Navigation Links
The 2013 HFSP Nakasone Award goes to Stephen Quake of Stanford University
Date:9/18/2012

The Human Frontier Science Program Organization (HFSPO) is pleased to announce that the 2013 HFSP Nakasone Award has been conferred upon Stephen Quake of Stanford University for his pioneering inventions and discoveries that made innovative physical techniques available for biology and that are revolutionizing biophysics, biological automation, genome analysis, and personalized medicine. His work is making it easy to answer and, in some cases, to ask questions that were previously impossible to address, and has profound impact for nearly every area of biology.

The HFSP Nakasone Award was established to honour scientists who have made key breakthroughs in fields at the forefront of the life sciences. It recognizes the vision of former Prime Minister Nakasone of Japan in the creation of the Human Frontier Science Program. Stephen Quake will present the HFSP Nakasone Lecture at the annual meeting of HFSP awardees to be held in Strasbourg, France, in July 2013.

Through his work Stephen Quake developed key technologies that enabled advances in a broad range of fields from single molecule biophysics to molecular biology and microbial ecology. New large-scale quantitative approaches are revolutionizing nearly every aspect of the biological sciences. Stephen Quake is directly responsible for a truly remarkable number of these innovations, which is reflected in the large number of widely cited papers and patents he has published.

Quake and his group developed a precision method for time-resolved force spectroscopy called FemtoNewton Force Spectroscopy which enables a deeper understanding of both colloidal hydrodynamics and DNA force fluctuations. He was also the first to demonstrate single molecule DNA sequencing, followed by its successful commercialization as not only the first single molecule sequencer, but also the first sequencer of any kind capable of sequencing the human genome with a single instrument.

His pioneering efforts extend to the field of microfluidics and its application to biophysics. Microfluidics, which is essentially miniaturized plumbing, offers the possibility of solving outstanding automation issues in biology and chemistry. Stephen Quake's basic research in this area has led to the development of new biophysical measurement technology and its application to a broad variety of questions. One of his seminal contributions in this field was the development of the first microfluidic large-scale integration, fabricating chips with thousands of mechanical valves, fundamentally redefining the field.

Steven Quake has used this new technology to explore a number of questions of fundamental biophysical interest, such as the development of physics-based approaches to protein crystallization and structural biology, the application of molecular affinity measurements to large-scale mapping of transcription-factor binding properties, and the development of single cell genomics.

Stephen Quake is Professor of Bioengineering and a Howard Hughes Medical Institute Investigator at the James H. Clark Center, Department of Bioengineering at Stanford University, California, USA. His work has been honored in the past by prestigious awards including the 2012 Lemelson-MIT prize.


'/>"/>

Contact: Guntram Bauer
communications@hfsp.org
Human Frontier Science Program
Source:Eurekalert

Related biology news :

1. Neurobiologist Rodal wins New Innovator award
2. Madidi conservationist wins award at World Conservation Congress
3. MARC travel awards announced for 2012 American Society for Bone & Mineral Research annual meeting
4. MARC travel awards announced for the 2012 APS Integrative Biology of Exercise meeting
5. MARC travel awards announced for the 2012 SACNAS Annual Meeting
6. Stanford bioengineer Christina Smolke wins NIH Directors Pioneer Award
7. A rare feat: 2 scientists at Salk score NIH New Innovator Awards
8. Daniel Kahnemans Thinking, Fast and Slow wins best book award from academies
9. NIH New Innovator Award helps Sanford-Burnham scientist pursue high-risk, high-reward project
10. NIBIB and HHMI announce graduate biomedical training awards
11. Jay Keasling wins Heinz Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... RPS ... clinical study that demonstrates the accuracy of the FebriDx® test, a commercially-ready, ... acute bacterial and viral respiratory tract infections by testing the body’s immune ...
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
Breaking Biology Technology: